DrugPatentWatch Database Preview
Drugs in Development Information for Motesanib
» See Plans and Pricing
What is the drug development status for Motesanib?
Motesanib is an investigational drug.
There have been 13 clinical trials for Motesanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2012.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Takeda.
Summary for Motesanib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 266 |
| WIPO Patent Applications | 1,498 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2012-07-01) |
| Vendors | 71 |
Recent Clinical Trials for Motesanib
| Title | Sponsor | Phase |
|---|---|---|
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Amgen | Phase 1/Phase 2 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Susan G. Komen Breast Cancer Foundation | Phase 1/Phase 2 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Sidney Kimmel Cancer Center at Thomas Jefferson University | Phase 1/Phase 2 |
Clinical Trial Summary for Motesanib
Top disease conditions for Motesanib
Top clinical trial sponsors for Motesanib
US Patents for Motesanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
